Bayer: collaboration deal with Recursion

(CercleFinance.com) - Bayer announces a strategic collaboration agreement with Recursion Pharmaceuticals, an American digital biology company that industrialises drug discovery.


The partnership will combine Recursion's artificial intelligence platform with Bayer's molecular library and scientific expertise to discover and develop new treatments for fibrous diseases of the lungs, kidneys, heart and other organs.

In addition, the German health and agrochemistry group says that its investment arm, Leaps by Bayer, is leading Recursion's Series D financing with an investment of 50 million dollars.


Copyright (c) 2020 CercleFinance.com. All rights reserved.